Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Big Brother Biotechnology-How Big Is Big?

Published 03/10/2020, 05:50 AM
Updated 07/09/2023, 06:31 AM

The ETF that holds Biogen (NASDAQ:BIIB), Regeneron (NASDAQ:REGN), Amgen (NASDAQ:AMGN), Gilead (NASDAQ:GILD) as four of the top ten in its basket, sits near the low price from two weeks ago (109.70).

I designed the Economic Modern Family with the notion of economic cyclicals and non-cyclicals.

In other words, the Family serves to measure the breadth of the economy by looking at supply, demand, retail, technology, both as the measures of consumer sentiment, regional banking and biotechnology.

Biotechnology is both a cyclical and non-cyclical sector.

In good economic times, pharma companies hire more, allocate more money to research and development plus attract a lot of speculators.

In poorer economic times, pharma companies tend to do better because folks need medication regardless.

With that said, health care costs, in general, will impact IBB’s performance as well.

Nasdaq Weekly Chart

In 2009, IBB was the first of the Economic Modern Family to bottom in price and improve in phase.

Now that the market has corrected about 20%, IBB is a sector to watch.

On the weekly chart note that yesterday’s inverted hammer doji-remember this-touched down on the 50-week moving average or blue line.

To review -An inverted hammer doji is created when the open, low and close are all around the same price.

Often, this candlestick pattern signals the end of the down move, or that a reversal is possible.

What troubles me the most right now, is how many people continue to think that this correction has given the market fair value.

What’s fair value?

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Should the oil and energy market continue to plummet, I fear we have yet to see “fair value.”

However, as unlikely as it seemed that volatility, after it made an inverted doji hammer back on February 5th, would climb, I will not overrule that IBB’s similar formation does not mean that this too can climb.

One fundamental aspect to IBB to consider is its role in finding a vaccine for the coronavirus.

At least, for now, we have a clear level to watch-109.70 with fudge.

S&P 500 (SPY) 285.54 the low from 2 weeks ago resistance. 273 closest support.

Russell 2000 (IWM) 140.00 resistance with 130 support then 127.75

Dow (DIA) 247 overhead resistance 236.00 the 200-WMA support

Nasdaq (QQQ) 199.27 the 200-DMA pivotal 185 underlying support

KRE (Regional Banks) Ouch. 35 support. 44 overhead resistance

SMH (Semiconductors) 125.00 now resistance. 112.50 support

IYT (Transportation) 155.24 the resistance or 2018 low. 143 then 139 support

IBB (Biotechnology) 109.70 to hold. 113 resistance to clear

XRT (Retail) 39.16 resistance 36.00-36.90 support

Volatility Index (VXX) 43 resistance 35 support

Junk Bonds (JNK) 98.76 2018 low

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.